Proud to be featured in TIME TIME100 Companies: New Frontiers, recognizing our work to reverse age-related diseases by targeting the biology of aging. We’re honored by this recognition & remain committed to advancing transformative therapies. Read more:
13,436 views
Welcome David Guyer, MD, to our Board of Directors! With over 30 years of drug development experience, he brings invaluable expertise as we continue advancing our Partial Epigenetic Reprogramming Platform toward the clinic in 2026. Read more:
40,512 views
We’ve closed a fully-subscribed $80 million financing to support our ongoing clinical trial in optic neuropathies and advancement of our Partial Epigenetic Reprogramming platform across multiple indications. Read more:
14,008 views
Q1 kicked off with strong momentum as our leadership team engaged across key industry forums, sharing perspectives on our Partial Epigenetic Reprogramming platform aimed at reversing age-related disease. Stay up to date on our progress:
12,547 views
We’re pleased to announce we’ve received FDA IND clearance for our cellular rejuvenation therapy using partial reprogramming for optic neuropathies, including glaucoma and NAION. Read more in our press release:
